康惠制药：创响盈累计质押公司股份约400万股

Group 1 - The core point of the article is that Kanghui Pharmaceutical announced significant shareholding and pledge details from a major shareholder, along with its revenue composition for the first half of 2025 [1] Group 2 - Kanghui Pharmaceutical's major shareholder, Shanghai Chuangxiangying Enterprise Management Partnership, holds approximately 5.99 million shares, accounting for 6% of the total share capital [1] - As of the announcement date, Chuangxiangying has pledged about 4 million shares, which is 66.67% of its holdings and 4% of the total share capital [1] - For the first half of 2025, Kanghui Pharmaceutical's revenue composition is as follows: 60.68% from pharmaceutical manufacturing, 36.79% from pharmaceutical distribution, and 2.53% from other businesses [1] - The current market capitalization of Kanghui Pharmaceutical is 2.4 billion yuan [1]